Cytodyn Inc (CYDY)

[justdafactss]

CD10 + CD12 both failed. And a single person in the Philippines approved to get lmab.

As the example shows here, where has CYDY said it met both primary and secondary endpoints?---

The phase III outcomes trial in high-risk non-hospitalised patients with COVID-19 met its primary endpoint, showing the investigational antibody cocktail of casirivimab and imdevimab reduced the risk of hospitalisation or death by 70% (1,200 mg intravenously [IV]) and 71% (2,400 mg IV) compared to placebo.

Casirivimab and imdevimab also met all key secondary endpoints in the phase III REGN-COV 2067 trial,
https://finance.yahoo.com/news/phase-iii-data-shows-investigational-060000368.html